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How can we achieve effective chemotherapy in highly  
advanced gastric cancer patients ?
Hideyuki UBUKATA
Fourth Department of Surgery, Tokyo Medical University Ibaraki Medical Center
The prognosis in highly advanced gastric cancer (unresectable or metastatic) is very poor, and chemotherapy 
is the main treatment in such patients. Anticancer agents against gastric cancer have diverse effects, and various 
regimens have been followed, but satisfactory results have not yet been achieved. Median survival times 
obtained in randomized controlled trials using such regimens have never exceeded two years. We have, there-
prognosis. Those patients with poor outcomes had a high neutrophil/lymphocyte ratio (NLR) or low Th1/Th2 
ratio. A negative linear correlation exists between these two factors, suggesting progressive collapse of immuno-
logical homeostasis. Furthermore, the ulti-
mate purpose of chemotherapy is the elimination of cancer cells, but the rapid loss of cancer tissue carries the risk 
of wall perforation in cancers of the alimentary tract. Therefore, it is necessary to maintain a balance between 
loss of cancer cells and replacement by normal tissues so that homeostasis is maintained. It is virtually impossi-
ble to eliminate all cancer cells by chemotherapy alone in highly advanced gastric cancer. Therefore, the second-
ary purpose of chemotherapy is to achieve concomitance with cancer cells, requiring a state of tumor dormancy.
Our previous study showed that NLR was affected by tumor size, indicating that tumor reduction is minimally 
essential for the maintenance of homeostasis. The notion of the response rate of the tumor to chemotherapy is 
still important. Consequently, there are two key factors that must be carefully considered in achieving effective 
chemotherapy in highly advanced gastric cancer patients : the maintenance of homeostasis and the process leading 
to tumor dormancy.
Gastric cancer is the second most frequent cause of 
death from cancer in Japan. Outcomes are extremely 
poor in patients with unresectable or metastatic gastric 
cancer, with a median survival time (MST) of 3 to 6 
months with best supportive care1). Several new 
anticancer agents have been developed and randomized 
controlled trials (RCTs) of various regimens including 
these drugs carried out. The results, however, have 
been disappointing.
Although these newer agents have shown some 
benefit,  chemotherapy alone has usually proven 
insufficient to rescue cancer patients. Realistically, 
there is no option other than to use the anticancer agents 
currently available. Therefore, it is necessary to 
consider unconventional approaches to these standard 
therapies in developing more effective anticancer 
chemotherapy. Cancers of the alimentary tract pose 
another major problem. Chemotherapy for such cancers 
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often causes acute loss of large amounts of cancer tissue, 
which may lead to perforation of the alimentary tract.
We are attempting to design new modes of chemotherapy 
against highly advanced gastric cancer by referring to the 
literature and our previous experience.
At present, the following anticancer agents are fre-
quently used to treat gastric cancer patients in Japan.
The drug 5- -
1957 as an antimetabolite agent, as reported by Dushin-
sky et al2) and Heidelberger et al3).
It is an analogue of the pyrimidine uracil4)5). In the 
5-FU molecule, the hydrogen atom in position 5 of uracil 
This 
molecule was designed to occupy the active sites of 
enzyme targets, thereby blocking metabolism in malig-
nant cells. It has been reported that two mechanisms 
could be partly responsible for the cytotoxic effect of 
5- -FU into 
DNA6) ; the second mechanism is the alteration of the 
membrane function of 5-FU-treated cells6). The activ-
ity of 5-FU is markedly limited by the action of the 
enzyme dihydropyrimidine dehydrogenase (DPD)6-8).
Skipper et al suggested that 5-FU has S-phase-specific 
cytotoxicity9) (Fig. 2).
Although 5-FU remains an essential agent in the treat-
ment of gastric cancer, its single-agent response rate is 
only 10%-30%.
Developed in Japan in 1996, S-1 is a prodrug of 5-FU10)
and a fourth-generation oral fluoropyrimidine, combin-
ing tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP ; 
gimestat), and potassium oxonate  (otastat) at a molar 
ratio of 1 : 0.4 : 110).
A potent and reversible inhibitor of DPD, CDHP pro-
longs high 5-FU concentration in the tumor, compensat-
ing for the weak point of 5-FU. In vitro, CDHP is 180 
times more potent than uracil, another reversible inhibi-
tor of DPD11).
Kinoshita et al reported that the response rate for neo-
adjuvant S-1 in gastric cancer was 60%, indicating that 
this drug is highly effective in reducing tumor size.
Capecitabine has the chemical name of N4-pentyloxy-
carbonyl- -deoxy-5-fluorocytidine. It is a cytotoxic 
agent that is administered orally. This agent was first 
synthesized in the 1990s in Japan13).
Capecitabine is also a prodrug of 5-FU and undergoes 
a three-step activation : first, in the liver, it is metabo-
- -DFCR) by hepatic 
-DFCR is deaminated to 
-FU by the enzyme thymidine 
phosphorylase6)7)14)15).
5-FU,  S-1,  and capeci tab ine  can be  o ra l ly 
administered. However, whereas S-1 is a DPD inhibi-
tor, the other two agents are not16).
Cis-diamminedichloroplatinum (II) (CDDP, cisplatin) 
was first described and reported by Peyrone in 194517).
It was shown to be one of the most active compounds in 
experimental tumor systems and was introduced into 
clinical practice in the early 1970s18).
Cisplatin is a DNA-damaging anticancer agent in which 
intra-strand DNA cross-links are the most common 
adducts formed, although inter-strand DNA cross-links 
and DNA protein cross-links can also occur19)20).
Therefore, CDDP is considered to have an inhibitory 
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effect on DNA synthesis (S phase in the cell cycle) (Fig. 
2). Moreover, Siddik et al21) reported that this drug 
suppressed RNA transcription in the cell cycle, resulting 
in the therapeutic induction of cancer cell apoptosis.
The chemical structures of taxanes are shown in Fig. 5.
Docetaxel is a semisynthetic analogue of paclitaxel, an 
Taxus brevifolia22)23).
Taxanes bind to and stabilize tubulin, which prevents 
physiological microtubule depolymerization/disassembly, 
resulting in cell-cycle arrest during the G2/M phase (Fig. 
2) and cell death24)25).
Wada et al26)
lular metabolic enzymes such as thymidine synthetase 
and DPD, which are involved in fluoropyrimidine 
resistance. These agents thereby act by being synergis-
tically cytotoxic to human gastrointestinal cancer cells.
Trastuzumab is a monoclonal antibody against human 
epidermal growth factor receptor 2 (HER2), which is a 
member of a family of receptors associated with tumor 
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cell proliferation, apoptosis, adhesion, migration, and 
differentiation27). HER2 is considered to be a key driver 
of tumorigenesis in gastric cancer, and its overexpression 
rates are reported to be 7%-34% in gastric cancer27-29).
Trastuzumab has been reported to have the following 
anticancer activity : a direct antiproliferative effect30) and 
an indirect antitumor effect due to antibody-dependent 
cellular cytotoxicity31)32).
In preclinical models of gastric cancer, trastuzumab 
showed anti tumor effects when combined with 
capecitabine33).
While 5-FU, S-1, capecitabine, and CDDP are cyto-
toxic agents, trastuzumab is a cytostatic agent.
5-FU is currently used as a core drug in the widely 
accepted international standard regimens used to treat 
gastric cancer, and the MST in inoperable gastric cancer 
treated with 5-FU alone is reported to be approximately 
7 months according to many RCTs.
Various regimens were followed, but no regimens sig-
-FU treat-
ment alone for some time. A novel breakthrough anti-
cancer agent, S-1, was developed in the 1990s, leading to 
a gradual improvement in the MST in highly advanced 
gastric cancer patients.
Ajani et al reported that S-1 in combination with 
CDDP was highly effective in Japanese gastric cancer 
patients34).
The SPIRITS trial was a randomized phase-III clinical 
trial of S-1 and high-dose CDDP (S-1 plus CDDP versus 
S- -line treatment of advanced gastric 
cancer. This trial demonstrated that MST was 
significantly longer in patients with advanced gastric 
cancer treated with S-1 plus CDDP (13.0 months) than in 
those treated with S-1 alone (11.0 months)35).
Furthermore, Schöffski reported that the combination 
of S-1 not only with CDDP, but also with docetaxel, was 
feasible and effective in the treatment of gastric cancer7).
Yoshida et al stated that the combination of docetaxel 
and S-1 was highly effective in advanced and recurrent 
gastric cancer, with an MST of 14.3 months36).
One s tudy of  t rastuzumab for  gastr ic cancer 
demonstrated that the median overall survival was 13.8 
months  in the tras tuzumab p lus chemotherapy 
the chemotherapy alone group ; and in the subgroup 
analysis, HER2-overexpression cases showed a median 
overall survival of 16.0 months37).
The above s tudies  show that  the MST with 
chemotherapy has gradually been increasing in 
inoperable, highly-advanced gastric cancer patients.
However, no regimen can extend MST for more than two 
years, indicating the need for further improvement.
It is important to examine the procedures and effects 
of chemotherapy, and similarly it is important to 
investigate the immunological/inflammatory conditions 
in gastric cancer patients treated with chemotherapy.
Therefore, we will now summarize our previous reports 
in relation to these aspects.
We previously reported that in preoperative data 
Docetaxel
Paclitaxel
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5-
granulocyte/lymphocyte (G/L) ratio group was better 
than that in the high G/L ratio group in gastric cancer 
patients who underwent curative surgery38). Also, there 
ratio regarding outcome (Fig. 6)38).
In Figure 6, zone A represents the intersection of the 
good outcomes are mostly present in this zone. On the 
high G/L ratio groups, includes many patients with poor 
outcomes.
Another of our previous reports showed that 5-year 
survival in the high Th1/Th2 ratio group was better than 
that in the low Th1/Th2 ratio group, and that that in the 
low neutrophil/lymphocyte ratio (NLR) group was 
greater than that in the high NLR group in gastric cancer 
patients undergoing curative surgery39). There was a 
negative linear correlation between Th1/Th2 ratio and 
NLR (Fig  7)39). Zone C in Fig. 7 includes many 
patients with good outcomes, but zone D includes mostly 
patients with poor outcomes.
The ultimate purpose of chemotherapy is the elimina-
tion of all cancer cells, but in highly advanced gastric 
cancer this is scarcely possible. Therefore, the second-
ary purpose of chemotherapy is to reduce tumor size, 
thereby decreasing concomitance. Tumor dormancy 
between cancer cells and hosts, as discussed in our previ-
ous report40).
Tumor dormancy is considered to be a state in which 
the normal, healthy tissues of the cancer-bearing host are 
concomitant with cancer cells. If the dormancy is dis-
turbed by infection or an immunosuppressive agent41), the 
prognosis of the cancer-bearing patient is reported to be 
poor42)43).
Two types of dormancy have been reported44)45), 
described as “dynamic” or “static”. Dynamic dormancy 
refers to a dynamic equilibrium between proliferation 
and apoptosis of cancer cells. In this state, various 
cytokines, such as EGF and VEGF, may play an impor-
tant role in cancer proliferation46)47)
in apoptosis48). Some immunotherapy may be effective 
in dynamic dormancy, such as inhibition of growth fac-
tors for cancer cells or induction of apoptosis in cancer 
cells. However, static dormancy implies mitotic arrest, 
the G0 phase in the cell cycle (Fig. 2)44
-46). In this state, 
since immunological tolerance may occur44), cancer-
bearing hosts cannot recognize cancer cells, and therefore 
there is no possibility of any immunotherapy being effec-
tive.
Conventional chemotherapies against gastric cancer 
show response rates of 30% to 40%35)49). Meta-analysis 
of phase II and III randomized gastric cancer trials has 
shown that combination chemotherapy results in 
substantially improved overall survival compared with 
single-agent chemotherapy or best supportive care37)50), 
but satisfactory increases in overall survival were not 
obtained35)49). This suggests that chemotherapy is 
relatively ineffective in cases of unresectable or recurrent 
gastric cancer, although treatment must be continued for 
the sake of the patient.
What key factors must be carefully considered in 
achieving effective chemotherapy in highly advanced 
gastric cancer patients ?
The problem is one of the need to design the most 
effective chemotherapy regimen with only a limited 
number of anticancer agents. Most antigastric cancer 
agents such as 5-FU, S1, capecitabine, and CDDP affect 
the synthetic phase in the cell cycle (Fig. 2). Inhibition 
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of DNA synthesis in cancer cells is considered to be very 
important in inhibiting progression in gastric cancer, 
indicating the need to concentrate our efforts against 
cancer cells during this phase. On the other hand, as 
some cancer cells may not be inhibited during this phase, 
inhibition during other phases is also of importance.
Agents belonging to the taxane group such as paclitaxel 
or docetaxel affect the mitotic phase in the cell cycle 
(Fig. 2). The combination of anticancer agents such as 
the fluoropyrimidines or CDDP with taxanes may be 
promising. An RCT of combination chemotherapy with 
S-1 and docetaxel is currently being conducted by the 
Japan Clinical Oncology Group, and the results are 
highly anticipated.
It is important not only to produce novel strong 
anticancer agents, but also to create the desirable 
conditions in cancer patients.
Our previous examinations revealed that negative linear 
L ratio38), and between the Th1/Th2 ratio and the NLR39).
51)
produced by antigen-activated monocytes/macrophages 
and T lymphocytes shows cytotoxic activity, inhibits 
tumor angiogenicity, and activates antitumor immunity52).
-
reported in apoptosis induction in various cancer cells, 
52-56).
supporting reports in the literature regarding the 
In contrast , some 
investigators have reported that gastric cancer cases with 
57)
induced tumor progression or inhibited apoptosis in 
cancer cells58). Why does this discrepancy occur ? Do 
concentration ?
examined from the point of view of its qualities, and it is 
therefore necessary to investigate other factors that 
interact with it.
Our group previously reported that a high G/L ratio in 
the peripheral blood is a good indicator of tumor progres-
sion in gastric cancer patients, and is a factor affecting 
survival59)60). Because of granulocytic proliferation in 
cancer patients with poor outcomes, these phenomena 
may be considered to be due to the action of cytokines 
considered to be produced not only by normal immuno-
competent cells in host patients, but also by gastric can-
cer cells61)62). Fig. 9 shows the cytokine network around 
CD4-positive T lymphocytes (Fig. 9). -
eration with interleukin 6 (IL6), has been reported to 
cause the conversion of CD4-positive T lymphocytes 
into Th17 cells63)64). Th17 cells produce IL17, which is 
considered to induce the proliferation of neutrophils63)65).
-positive T lymphocytes 
into T-regulatory lymphocytes (Treg)65)66). Treg is an 
immunosuppressive factor64), and therefore could cause a 
high G/L ratio, resulting in a poor outcome in gastric 
cancer patients62-67).
We also investigated immunological status in gastric 
cancer using the Th1/Th2 ratio. A Th1-dominant state 
showed a good outcome, and a high NLR state showed a 
poor outcome39).
It is still not clear why Th1-dominant immunity is 
more desirable in preventing cancer, but various patho-
gens can induce different immune responses that may 
correspond to Th1 or Th2 activation and dominance68).
This suggests that preventive immunological conditions 
Tumor dormancy
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differ depending on the disorder. For example, Th1-
dominant immunity prevents some viral infections, and 
Th2-dominant immunity protects against some 
parasites52)68). Therefore, Th1-dominant immunity may 
be needed for anticancer immunity.
Consequently, a high G/L ratio or NLR and low Th1/
Th2 ratio suggest the collapse of immunological homeo-
stasis in cancer hosts. Accordingly, the lines shown in 
Figures 6 and 7 from the upper left to the lower right 
indicate the pathway of collapse of immunological 
homeostasis (Fig. 6, 7).
These  resu l t s  ind ica te  tha t  mainte nance  o f 
good prognosis in gastric cancer patients. When the 
collapse of immunological homeostasis occurs in such 
-
positive T lymphocytes are insufficient to indicate 
anticancer ability. In this situation, no type of 
chemotherapy would be effective, and so it might be 
impossible to obtain favorable outcomes in such patients.
One of the aims of chemotherapy is the elimination of 
cancer cells, but it is accompanied with the risk of perfo-
ration of the gastric wall in highly advanced gastric can-
cer if homeostasis is not maintained. If the elimination 
of the tumor is too rapid and replacement with normal 
tissue delayed, perforation of the gastric wall may occur.
Therefore, even from this point of view, maintenance of 
homeostasis is significant in maintaining the balance 
between elimination of cancer cells and replacement with 
normal tissues.
Another important aim of chemotherapy is to achieve 
tumor dormancy. Dynamic dormancy is the state of 
competition between tumor progression and apoptosis in 
cancer cells, resulting in a counterfeit concomitance 
between the cancer cells and the host. In this state, vari-
ous cytokines show diverse anticancer effects, and che-
motherapy may be quite helpful40). However, with static 
dormancy, there is immunological tolerance. This 
means that chemotherapy will be less effective as immu-
-
ing cancer cells40). However, this would also mean that 
there was true concomitance between the cancer cells 
and the host.
Chemotherapy may still be effective with dynamic 
dormancy, in which immunological homeostasis is 
maintained. Tumor reduction may be indispensable in 
acquiring dynamic dormancy. In an earlier study, we 
found that NLR was a good prognostic indicator and that 
it was affected by tumor size39). Recently, we have been 
more concerned with survival time than with tumor 
response rates under chemotherapy, but the notion of 
reduction using conventional anticancer agents with 
cytotoxic effects should be attempted, resulting in a state 
of dynamic dormancy. Second, the additional use of 
molecularly-targeted drugs with cytostatic effects may 
be recommended in the acquisition of a final state of 
static dormancy.
However,  in  real i ty,  var ious  immunological 
obstructions, inhibitions, or interruptions against the 
effects of anticancer agents may be present in cancer 
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hosts,  making acceptable results  unobtainable.
Nevertheless, we should still exert every effort and must 
continue to propose various protocols for chemotherapies 
in order to defeat cancer and rescue gastric cancer 
patients.
and practical suggestions to achieve desirable conditions 
in gastric cancer patients in whom chemotherapies are 
currently implemented, we are continuously making 
in-depth investigations to address this issue.
In conclusion, although a precise statement cannot 
readily be made in answer to the title question of the 
present article, the current review suggests that 
maintenance of immunological homeostasis in cancer 
hosts and therapy leading to tumor dormancy are the two 
key factors that must be focused on in order to achieve 
effective chemotherapy in highly advanced gastric cancer 
patients. The NLR or G/L ratio and Th1/Th2 ratio may 
be good indicators in evaluating these two key factors.
The authors are indebted to Prof. Jeremy Williams of 
the Department of International Medical Communica-
tions of Tokyo Medical University for his careful linguis-
tic assistance with this manuscript.
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